| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/24/2026 | ±4.0% | -2.5% | over-priced |
| 04/24/2026 | ±3.7% | -25.5% | under-priced |
| 01/30/2026 | ±4.0% | +7.6% | under-priced |
| 10/31/2025 | ±3.9% | +1.3% | over-priced |
| 07/25/2025 | ±2.8% | -18.5% | under-priced |
| 04/25/2025 | ±4.3% | +11.4% | under-priced |
| 01/31/2025 | ±4.2% | +2.6% | over-priced |
| 11/01/2024 | ±3.4% | +11.9% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $10.66 | $13.5B | $1.3B |
| Q1 FY2026 | $9.17 | $13.6B | $1.2B |
| Q4 FY2025 | — | $13.6B | $1.3B |
| Q3 FY2025 | $8.34 | $13.7B | $1.1B |
CHTR (CHTR) reports in 85 days, with the next report estimated for 01/20/2027. Across the last 8 reports, options priced an average ±3.8% earnings move while the stock actually moved 10.2% on average — the market has been roughly fair on CHTR's earnings risk. Fundamentals into the print: EPS up 16.1% year-over-year, revenue down 1.7%. QuantLogix's live 5-factor engine currently reads CHTR as a underweight at 46/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →